Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review.

Front Cardiovasc Med · 2021 · PMC8631913 · PMID 34859070

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

clearly significantno p-value reported

As previously discussed, its efficacy in reducing the combined risk of death from CV causes or hospitalization for HF in patients with HFrEF was demonstrated in the PARADIGM-HF study, which was prematurely stopped because it exceeded the threshold of a clearly significant benefit ( 5 ).

also in 627 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.